RealTime Dynamix™: Rheumatoid Arthritis US Q3 2018 Spotlight
US Rheumatologists’ early views on Eli Lilly’s Olumiant for the treatment of rheumatoid arthritis show uphill battle, while Pfizer’s Xeljanz holds ground as the preferred JAK inhibitor. The below complimentary highlights were taken from the Q3 2018 wave of RealTime Dynamix: Rheumatoid Arthritis US. The next wave of this study will field in November 2018 and will continue to track the launch of Olumiant and Kevzara, uptake of biosimilars, as well as the overall evolving US RA market. The second annual wave of a parallel study tracking the evolution of the European RA market will publish at the end of December 2018.
Contact [email protected] for more information about the highlighted reports or to see if your company already has access to the US or EU report series.
All company, brand or product names and logos in this document are trademarks of their respective holders.